Economic evaluation and end-stage renal disease: From basics to bedside

American Journal of Kidney Diseases

Volumn 36, Issue 1, 2000, Pages 12-28

  Manns, B J ^a   Taub, K J ^a   Donaldson, C ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cost analysis; Cost utility; Cost effectiveness; Dialysis; Economic evaluation; End stage renal disease (ESRD); Health economics; Kidney failure; Review

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; ERYTHROPOIETIN; HEPATITIS B VACCINE; IRON; UROKINASE;

CANCER SCREENING; CLASSIFICATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; META ANALYSIS; OUTCOMES RESEARCH; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW;

EID: 0033916217     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2000.8235     Document Type: Article

References (68)

1. US Renal Data System The economic cost of ESRD, vascular access procedures, and Medicare spending for alternative modalities of treatment Am J Kidney Dis 30 suppl 1 1997 S160 S177
2. S Garella The costs of dialysis in the USA Nephrol Dial Transplant 12 suppl 1 1997 S10 S21
3. NP Mallick The costs of renal services in Britain Nephrol Dial Transplant 12 suppl 1 1997 S25 S28
4. CRV Tomson Recent advances in nephrology BMJ 320 2000 98 101
5. C Donaldson P Shackley Economic evaluation ed 3 R Detels WW Holland J McEwan GS Omenn Oxford Textbook of Public Health 1997 Oxford University Press Oxford, UK 849 870
6. R Goeree J Manalich P Grootendorst ML Beecroft DN Churchill Cost analysis of dialysis treatments for end-stage renal disease (ESRD) Clin Invest Med 18 1995 455 464
7. S Fenton D Schaubel M Desmeules H Morrison Y Mao P Coplestone J Jeffrey C Kjellstrand Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates Am J Kidney Dis 30 1997 334 342
8. RN Foley PS Parfrey JD Harnett GM Kent R O'dea DC Murray PE Barre Mode of dialysis therapy and mortality in end-stage renal disease J Am Soc Nephrol 9 1998 267 276
9. W Bloembergen S Port E Mauger R Wolfe A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis J Am Soc Nephrol 6 1995 177 183
10. AJ Collins W Hao H Xia JP Ebben SE Everson EG Constantini JZ Ma Mortality risks of peritoneal dialysis and hemodialysis Am J Kidney Dis 34 1999 1065 1074
11. MB Hamel RS Phillips RB Davis N Desbiens AF Connorrs JM Teno N Wenger J Lynn AW Wu W Fulkerson J Tsevat Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults Ann Intern Med 127 1997 195 202
12. MF Drummond WS Richardson BJ O'Brien M Levine D Heyland Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice: A. Are the results of the study valid? JAMA 277 1997 1552 1557
13. BJ O'Brien D Heyland WS Richardson M Levine MF Drummond Users' guides to the medical literature: XIII. How to use an article on economic analysis of clinical practice: B. What are the results and will they help me in caring for my patients? JAMA 277 1997 1802 1806
14. A Laupacis D Feeny AS Detsky PX Tugwell How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations Can Med Assoc J 146 1992 473 481
15. J Mason M Drummond G Torrance Some guidelines on the use of cost-effectiveness league tables BMJ 306 1993 570 572
16. TW Wilson A Chockalingam DW Quest Pharmacoeconomics of hypertension control: Basic principles of economic evaluation J Hum Hypertens 10 suppl 2 1996 S19 S22
17. M Johannesson B Jonsson J Kjekshus AG Olsson TR Pedersen H Wedel Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease N Engl J Med 336 1997 332 336
18. J Caro W Klittich A McGuire I Ford J Norrie D Pettitt J McMurray J Shepherd The West of Scotland coronary prevention study: Economic benefit analysis of primary prevention with pravastatin BMJ 315 1997 1577 1582
19. CE Douma WK Redekop JH van der Meulen RW van Olden J Haeck DG Struijk RT Krediet Predicting mortality in intensive care patients with acute renal failure treated with dialysis J Am Soc Nephrol 8 1997 111 117
20. KM Kuntz J Tsevat L Goldman MC Weinstein Cost-effectiveness of routine coronary angiography after acute myocardial infarction Circulation 94 1996 957 965
21. A Gafni S Birch Guidelines for the adoption of new technologies: A prescription for uncontrolled growth in expenditures and how to avoid the problem Can Med Assoc J 148 1993 913 917
22. A MacLeod A Grant C Donaldson I Khan M Campbell C Daly P Lawrence S Wallace L Vale J Cody K Fitzhugh G Montague C Ritchie Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: Systematic reviews Health Technol Assess 2 1998 1 143
23. A Laupacis P Keown N Pus H Krueger B Ferguson C Wong N Muirhead A study of the quality of life and cost-utility of renal transplantation Kidney Int 50 1996 235 242
24. CJ Foulks An evidence-based evaluation of intradialytic parenteral nutrition Am J Kidney Dis 33 1999 186 192
25. JD Kopple D Bernard J Messana R Swartz J Bergstrom B Lindholm V Lim G Brunori M Leiserowitz DM Bier LD Stegink L Martis CA Boyle KD Serkes E Vonesh MR Jones Treatment of malnourished CAPD patients with an amino acid-based dialysate Kidney Int 47 1995 1148 1157
26. EG Lowrie NM Laird TF Parker JA Sargent Effect of hemodialysis prescription on patient morbidity: Report from the National Cooperative Dialysis Study N Engl J Med 305 1981 1176 1181
27. B Charra E Calemard M Ruffet C Chazot J Terrat T Vanel G Laurent Survival as an index of adequacy of dialysis Kidney Int 41 1992 1286 1291
28. RA Hirth PJ Held SM Orzol A Dor Practice patterns, case mix, Medicare payment policy, and dialysis facility costs Health Serv Res 33 1999 1567 1592
29. JC Hornberger The hemodialysis prescription and cost-effectiveness J Am Soc Nephrol 4 1993 1021 1027
30. G Eknoyan AS Levey GJ Beck LY Agodoa JT Daugirdas JW Kusek NW Levin G Schulman The Hemodialysis (HEMO) Study: Rationale for selection of interventions Semin Dial 9 1996 24 33
31. DA Ogden G Kopec AD Guy Cost effectiveness of multiple dialyzer use Dial Transplant 10 1981 407 411
32. JP Held RA Wolfe DS Gaylin FK Port NW Levin MN Turenne Analysis of the association of dialyzer reuse practices and patient outcomes Am J Kidney Dis 23 1994 692 708
33. AJ Collins JZ Ma EG Constantini SE Everson Dialysis unit and patient characteristics associated with reuse practices and mortality: 1989-1993 J Am Soc Nephrol 9 1998 2108 2117
34. HI Feldman M Kinosian WB Bilker C Simmons JH Holmes MV Pauly JJ Escarce Effect of dialyzer reuse on survival of patients treated with hemodialysis JAMA 276 1996 620 625
35. HI Feldman WB Bilker MH Hackett CW Simmons JH Holmes MV Pauly JJ Escarce Association of dialyzer reuse with hospitalization and survival rates among US hemodialysis patients: Do comorbidities matter? J Clin Epidemiol 52 1999 209 217
36. DA Luehmann LC Cosentino Safety of dialyzer reuse with Renalin: The untold story Dial Transplant 23 1994 248 249
37. US Renal Data System USRDS 1996 Annual Data Report. The National Institutes of Health 1996 National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 33 43
38. IC MacDougall B Tucker J Thompson CRV Tomson LRI Baker AEG Raine A randomized controlled study of iron supplementation in patients treated with erythropoietin Kidney Int 50 1996 1694 1699
39. F Sepandj K Jindal M West D Hirsch Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients Nephrol Dial Transplant 11 1996 319 322
40. A Levin M Lewis P Mortiboy S Faber I Hare EC Porter DC Mendelssohn Multidisciplinary predialysis programs: Quantification and limitations of their impact on patient outcomes in two Canadian settings Am J Kidney Dis 29 1997 533 540
41. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older patients with isolated systolic hypertension JAMA 265 1991 3255 3264
42. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure Arch Intern Med 157 1997 2413 2446
43. I Kawachi LA Malcolm The cost-effectiveness of treating mild-to-moderate hypertension: A reappraisal J Hypertens 9 1991 199 208
44. JD Neaton RH Grimm RJ Prineas J Stamler GA Grandits PJ Elmer JA Cutler JM Flack JA Schoenberger R McDonald Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group JAMA 270 1993 713 724
45. RN Foley PS Parfrey MJ Sarnak Epidemiology of cardiovascular disease in chronic renal disease J Am Soc Nephrol 9 suppl 4 1998 S16 S23
46. B Leese J Hutton A Maynard The Costs and Benefits of the Use of Erythropoietin in the Treatment of Anaemia Arising from Chronic Renal Failure: A European Study 1990 University of York York, UK Centre for Health Economics Occasional Paper
47. P McNamee E van Doorslaer R Segaar Benefits and costs of recombinant human erythropoietin for end-stage renal failure: A review Int J Technol Assess Health Care 9 1993 490 504
48. SH Sheingold DN Churchill N Muirhead A Laupacis Recombinant human erythropoietin: Factors to consider in cost-benefit analysis Am J Kidney Dis 17 1991 86 92
49. AM Grimm KK Flaharty LE Hopkins J Mauskopf A Besarab PH Vlasses Economics of epoetin therapy Clin Pharmacol 8 1989 807 810
50. ME Stevens GP Summerfield AA Hall CA Beck AJ Harding JR Cove-Smith AD Paterson Cost benefits of low-dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease BMJ 304 1992 474 477
51. A Laupacis C Wong DN Churchill The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin Control Clin Trials 12 suppl 4 1991 S168 S179
52. Canadian Erythropoietin Study Group Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis BMJ 300 1990 573 578
53. GM Chertow J Ling NL Lew JM Lazarus EG Lowrie The association of intradialytic parenteral nutrition administration with survival in hemodialysis patients Am J Kidney Dis 24 1994 912 920
54. CJ Foulks An evidence-based evaluation of intradialytic parenteral nutrition Am J Kidney Dis 33 1999 186 192
55. RM Hakim Proposed clinical trials in the evaluation of intradialytic parenteral nutrition Am J Kidney Dis 33 1999 217 220
56. S Emili NA Black RV Paul CJ Rexing ME Ullian A protocol-based treatment for intradialytic hypotension in hospitalized hemodialysis patients Am J Kidney Dis 33 1999 1107 1114
57. Cochrane Injuries Group Albumin Reviewers Human albumin administration in critically ill patients: Systematic review of randomised controlled trials BMJ 317 1998 235 240
58. Canada-USA Peritoneal Dialysis Study Group Adequacy and nutrition in continuous peritoneal dialysis: Association with clinical outcomes J Am Soc Nephrol 7 1996 198 207
59. JD Kopple D Bernard J Messana R Swartz J Bergstrom B Lindholm V Lim G Brunori M Leiserowitz DM Bier LD Stegink L Martis CA Boyle KD Serkes E Vonesh MR Jones Treatment of malnourished CAPD patients with an amino acid-based dialysate Kidney Int 47 1995 1148 1157
60. M Jones T Hagen CA Boyle E Vonesh R Hamburger C Charytan S Sandroni D Bernard B Piraino M Schreiber T Gehr P Fein M Friedlander J Burkart D Ross S Zimmerman R Swartz T Knight A Kraus L McDonald M Hartnett M Weaver L Martis J Moran Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicenter outpatient study Am J Kidney Dis 32 1998 761 769
61. HRH Brulez C van Guldener AJM Donker PM ter Wee The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass Nephrol Dial Transplant 14 1999 154 159
62. A Bostom L Lathrop Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes Kidney Int 52 1997 10 20
63. ZJ Twardowski High-dose intradialytic urokinase to restore the patency of permanent central vein hemodialysis catheters Am J Kidney Dis 31 1998 841 847
64. GM Chertow D Paltiel WF Owen M Lazarus Cost-effectiveness of cancer screening in end-stage renal disease Arch Intern Med 156 1996 1345 1350
65. A Besarab WK Bolton JK Browne JC Egrie AR Nissenson DM Okamoto SJ Schwab DA Godkin The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590
66. V Bonomini L Baldrati S Stefoni Comparative cost/benefit analysis in early and late dialysis Nephron 33 1983 1 4
67. TI Garner R Dardis Cost-effectiveness analysis of end-stage renal disease treatments Med Care 25 1987 25 34
68. FN Hutchison WJ Jones A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease Am J Kidney Dis 29 1997 651 657